Stock with Momentum: Tianjin Pharmaceutical Da Ren Tang

March 14, 2024

In today’s fast-paced stock market, understanding the subtle cues of technical analysis is key to smart investing.

In this article, we focus on Tianjin Pharmaceutical Da Re Tang Group Corp Ltd (SGX: T14), whose price action is indicating a potential end to a downward correction and a return to the upside.

Below are some key highlights from the technical report:

  • Market Position: Tianjin Pharma is designated as a ‘Technical Buy’ at the last price of US$1.98.
  • Entry Prices and Support Levels: Suggested entry prices are US$1.98, US$1.84 and US$1.72, with key supports at US$1.85 and US$1.65.
  • Stop Loss and Resistance Levels: A stop loss is advised at US$1.62, with resistance points at US$2.10 and US$2.30.
  • Target Prices: The analysis sets target prices at US$2.28, US$2.46, US$2.66, and US$2.84.
  • Company Overview: Tianjin Pharma produces and sells traditional Chinese medicine, western medicine, health products, and healthcare instruments.

For a more detailed analysis, click on the link to access the report.

Take advantage of the stock momentum

Our goal is simple: to provide you with clear, actionable insights from the complex world of stock charts and trends. Whether you’re a seasoned investor or just starting out, our analysis is designed to help you navigate the market with confidence.

Please refer to the attached report for the disclaimer.

Chua Wei Ren, CMT

With over 12 years’ experience, Wei Ren is a market strategist who specialises in Technical Analysis and Macro Economics. Leveraging core price action trading strategy with classical technical analysis to spot market movements for entries and exits, he believes that historical data plays a pertinent role in how market prices would impact future trades. Wei Ren also writes for CGSi Trendspotter, a daily market outlook report that aims to identify trading ideas in Singapore, as well as China and Hong Kong’s equity markets. A seasoned presenter, he has been hosting live webinars since the start of his career as a market strategist and has been featured on various mainstream media platforms including The Business Times ‘Chart Point’ and Capital 95.8.

Share this

Subscribe to our weekly
newsletter and stay updated!